BRUKINSA is a BTK inhibitor that
was designed to block BTK
BRUKINSA® (zanubrutinib) has been shown to block 100% of BTK in blood cells and 94% to 100% of BTK in lymph nodes when taken at the recommended total daily dose of 320 mg. The significance of blocking up to 100% of BTK on treatment responses has not been established.
BRUKINSA is a prescription
medicine used to treat adults with
Waldenström’s macroglobulinemia (WM).
Bruton’s tyrosine kinase (BTK) is a protein that has been linked to WM.
Patient Support Program
To meet your individual needs, myBeiGene pairs you with a
dedicated Oncology Nurse Advocate who will personalize support
for you and your caregivers during your treatment with
BRUKINSA.
access to
BRUKINSA
BRUKINSA
personalized
solutions